Harrow Inc. (HROW)
HROW trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1360214/000149315226008562/0001493152-26-008562-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | HROW on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001360214 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $272.3M |
| Net income | -$5.1M |
| Operating income | $30.5M |
| Net margin | -1.9% |
| Operating margin | 11.2% |
| Revenue growth | +36.4% |
| Cash | $72.9M |
| Total assets | $399.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $75.3M cash; operating cash flow -$4.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 37,533,160 (2026-11-05); 37,037,453 a year earlier; 35,117,746 three years earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2025-10-10 |
| Auditor | Deloitte & Touche LLP, Nashville, Tennessee, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-09-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $469K, sold $9.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $99.3M | $9.8M | -$8.6M | $75.3M | No debt tags | $303.3M | 10-Q 2026-11-09 |
| Q2 2026 2026-06-30 | $70.7M | -$17.3M | -$9.8M | $83.9M | No debt tags | $275.6M | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | $44.2M | -$27.6M | -$9.0M | $94.6M | $300.0M | $268.7M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $89.1M | $6.6M | $8.4M | $72.9M | $250.0M | $272.3M | 10-K 2026-03-02 |
| Q3 2025 2025-09-30 | $71.6M | $1.0M | $16.6M | $74.3M | $347.2M | $250.0M | 10-Q 2026-11-09 |
| Q2 2025 2025-06-30 | $63.7M | $5.0M | -$803K | $53.0M | $250.6M | $227.7M | 10-Q 2026-08-10 |
| Q1 2025 2025-03-31 | $47.8M | -$17.8M | $19.7M | $66.7M | $256.9M | $212.9M | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $66.8M | $6.8M | -$17.8M | $47.2M | $262.7M | $199.6M | 10-K 2026-03-02 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2023-07-19 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 873 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +12.0% |
| 1 month | +6.7% |
| 3 months | -22.5% |
| Year to date | -38.5% |
| 1 year | -20.5% |
| From 52-week high | -45.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ANRO | Alto Neuroscience Inc. | $27.12 | -8.19% | $1.1B |
| MTRI | Mentari Therapeutics Inc. | $19.87 | +6.83% | $1.0B |
| SPTX | Seaport Therapeutics Inc. | $19.12 | -4.30% | $1.0B |
| CMPS | COMPASS Pathways Plc American Depository Shares | $8.27 | -8.21% | $1.2B |
| CYRX | CryoPort Inc. | $19.80 | -0.45% | $1.0B |
| MLTX | MoonLake Immunotherapeutics | $11.73 | -6.16% | $998.3M |
| KARD | Kardigan Inc. | $12.85 | -7.02% | $1.2B |
| OPK | OPKO Health Inc. | $1.62 | -3.57% | $1.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier